Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman

Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman

BOCA RATON, Fla., March 11, 2010 /PRNewswire-FirstCall/ -- Stem Cell Assurance is pleased to announce the inclusion of one of the Cleveland Clinic's 2010 Best Doctors, Dr. Joseph J. Ross, M.D., F.A.C.S. Dr. Ross will officially take up Vice Chairmanship for the company in March 2010. Stem Cell Assurance welcomes his appointment to strengthen operations of their national physician network designed to provide medical and cosmetic procedures and cell banking to individual clients. This latest development for Stem Cell Assurance follows the company's exponential growth in practice locations with the addition of many industry-leading physicians.

Dr. Ross's experience makes him ideally placed to assume a central role within Stem Cell Assurance. He currently holds professional positions at Envision Eye Specialists in Crystal River, Florida and The Omni Eye Institute in Ocala, Florida and is licensed in the states of Ohio, Arizona, and Florida. He obtained his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio and completed a fellowship in ophthalmic and facial cosmetic and reconstructive plastic surgery at the University of Arizona under renowned Preceptor Robert M. Dryden, M.D. 

Dr. Ross is board certified in ophthalmology. He is a fellow of the American Academy of Facial Plastic Surgeons, the American Society of Ophthalmic Plastic and Reconstructive Surgeons, the American College of Surgeons, the Ohio State Medical Society, and the Florida Medical Association, among six other major memberships. He is currently the Director of Oculoplastics Service at MetroHealth Medical Center in Cleveland, Ohio and Assistant Clinical Professor in the Department of Dermatology at Case Western Reserve University School of Medicine.

 

Dr. Ross has authored publications on topics including cancer, facial contouring, dermal fat grafts, and facial implants. His work has been included in major publications including The Journal of Dermatologic Surgery and Oncology and Ophthalmic Plastic and Reconstructive Surgery. He has presented and lectured extensively on such topics as plastic, cosmetic, and reconstructive surgery techniques and office procedures; skin cancer detection and management; facelifts; nose reconstruction; skin care including products, chemical peels, microdermabrasion, and lasers; and micrografting.

 

As the new Vice Chairman of Stem Cell Assurance, Dr. Ross commented "Stem Cell Assurance, which offers invaluable bioinsurance services through stem cell banking and other exciting cosmetic applications, dovetails perfectly with my feelings towards the potential of stem cells to discover better therapies and ultimately even cures for debilitating diseases. Stem Cell Assurance is ready to monetize its extensive assets and deliver its branded services to clients and patients. I am eager to come aboard as Vice Chairman at this time of great growth in the company, and I look forward to the road ahead."

 

 

Stem Cell Assurance, Inc. is the first company in the US to provide full-spectrum adult stem cell services to consumers through a national physician network. The company offers genetic profiling services and consultation, adult stem cell research, and stem cell collection, processing, and cryogenic storage, as well as cosmetic and other infusion therapies. The company is based in Boca Raton, Florida. See www.stemcellassurance.com for more information.

 

Investor Relations:

 

Equiti-Trend Advisors

800-953-3350

 

 

CONTACT: Investor Relations: Equiti-Trend Advisors: 800-953-3350

Web site: http://www.stemcellassurance.com/

Suggested Articles

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.

The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.